### Guideline Page and Request

**Internal request:**
Suggestion was made to add the option of imatinib mesylate for patients with recurrent disease who are unresectable.

### Panel Discussion

Based on available data and discussion the panel consensus was to change the recommendation for the treatment of patients with recurrent disease to the following: "Imatinib mesylate in cases where disease is unresectable or unacceptable functional or cosmetic outcomes will occur".

### References


### Vote

<table>
<thead>
<tr>
<th></th>
<th>YES</th>
<th>NO</th>
<th>ABSTAIN</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>18</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>